CAELUS PHARMACEUTICALS
LIVE

Serial Number

79222834

Owner

Caelus Pharmaceuticals B.V.

Attorney

Roberto Ledesma

Filing Date

Jun 1, 2017

Add to watchlist:

No watchlists yet
View on USPTO

CAELUS PHARMACEUTICALS Trademark

Serial Number: 79222834 • Registration: 5619593

CAELUS PHARMACEUTICALS is a trademark filed by Caelus Pharmaceuticals B.V. on June 1, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Caelus Pharmaceuticals B.V. (9 trademarks)

Rondweg 50

Entity Type: 98

Trademark Details

Filing Date

June 1, 2017

Registration Date

December 4, 2018

Published for Opposition

September 18, 2018

Goods & Services

[ Medical apparatus and instruments, namely, for use in treating cardiovascular disease or diabetes, for monitoring vital signs, blood sugar levels, AGE-levels in the skin and gut/skin microbiota composition; Medical diagnostic, testing and monitoring equipment, namely, medical diagnostic equipment for detecting and monitoring blood sugar levels, AGEs and microbiome composition; testing apparatus for medical use, namely, medical devices for testing blood glucose, microbiome composition in gut and on the skin, testing AGE-levels, and for testing the levels of butyrate in breath analysis; measuring devices for medical use, namely, medical device for measuring glucose, insulin, butyrate, propionate, gut and skin microbiome; testing apparatus for medical use, namely, blood testing apparatus, apparatus for analyzing feces or respiratory gas, medical measuring devices for medical use, namely, devices for measuring microorganisms or gas; medical test kits for home monitoring of diabetes ]

Pharmaceutical products for treating cardiometabolic disorders; dietetic foodstuffs adapted for medical use and dietetic substances, namely, dietetic foods adapted for medical use; food supplements for human beings; medical preparations and articles for the treatment of cardiometabolic disorders; [ diagnostic preparations for medical use; pharmaceutical products and natural medicines, both for the treatment of cardiometabolic disorders; vaccines; ] pharmaceutical preparations, namely, medicines [ and vaccines, ] for the prevention of diabetes mellitus [ , Crohn's disease and ulcerative colitis disease ] ; pharmaceutical preparations, namely, medicines for the treatment of diabetes mellitus, [ Crohn's disease, ulcerative colitis disease ] and metabolic syndrome being insulin resistance; dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic preparations, namely, dietary supplements; dietary food preparations, namely, dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the prevention of diabetes mellitus [ , Crohn's disease and ulcerative colitis disease ] ; dietary food preparations, namely, dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the treatment of diabetes mellitus [ , Crohn's disease, ulcerative colitis disease ] and metabolic syndrome being insulin resistance; medical preparations, namely, cultures of microorganisms for medical use, and bacterial preparations for medical use [ ; chemicals for the diagnosis of diabetes mellitus, Crohn's disease and ulcerative colitis disease; vaccine preparations for human use ]

Filing History

GENERIC MADRID TRANSACTION SENT TO IB
Jul 8, 2026 XXSS
GENERIC MADRID TRANSACTION CREATED
Jul 8, 2026 XXCR
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Jul 8, 2026 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 7, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Apr 7, 2025 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Apr 7, 2025 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 7, 2025 APRE
TEAS SECTION 71 RECEIVED
Nov 14, 2024 ES71
NEW REPRESENTATIVE AT IB RECEIVED
Dec 30, 2023 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 4, 2023 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 5, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 18, 2019 FICS
FINAL DISPOSITION PROCESSED
Mar 18, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 4, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 4, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 18, 2018 NPUB
PUBLISHED FOR OPPOSITION
Sep 18, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Sep 15, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 29, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 29, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 29, 2018 NONP
ASSIGNED TO LIE
Aug 13, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 2, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 2, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 2, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 2, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 2, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 6, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 6, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 6, 2018 TROA
REFUSAL PROCESSED BY IB
Feb 16, 2018 RFNT
NEW REPRESENTATIVE AT IB RECEIVED
Feb 15, 2018 NREP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 12, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jan 12, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 23, 2017 RFCR
APPLICATION FILING RECEIPT MAILED
Dec 23, 2017 MAFR
NON-FINAL ACTION WRITTEN
Dec 22, 2017 CNRT
ASSIGNED TO EXAMINER
Dec 19, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 19, 2017 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Dec 18, 2017 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 14, 2017 REPR